Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 246 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Adult Males Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Tablet and Capsule Bioavailability Study

NCT02448368
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170, 10 mg, RDEA3170, 2.5 mg, RDEA3170, 5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT04966325
View directory record Official record
Conditions
Hyperuricemia, Gout, Qt Interval, Variation in
Interventions
LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

NCT03563846
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

NCT04241393
View directory record Official record
Conditions
Healthy Subjects
Interventions
Tavapadon tablet, Tavapadon [14C] suspension
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

NCT06586671
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men

NCT00287833
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
placebo, Bowman-Birk inhibitor concentrate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of SQ109 in Healthy Adult Volunteers

NCT00866190
View directory record Official record
Conditions
TB Multi-drug Resistant
Interventions
SQ109, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

NCT06562985
View directory record Official record
Conditions
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
Interventions
BAY3018250 Dose 1, Placebo, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

NCT00823745
View directory record Official record
Conditions
HCV
Interventions
[14C]-PF-00868554
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2009 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

NCT01299805
View directory record Official record
Conditions
Healthy
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

NCT03945760
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Wright State Physicians
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad Tablet Bioequivalence

NCT02127775
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg (manufactured at Site 1), Lesinurad 400 mg (manufactured at Site 2)
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

NCT03202693
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

NCT01631487
View directory record Official record
Conditions
Healthy
Interventions
JNJ-39439335 10 mg, JNJ-39439335 25 mg, JNJ-39439335 50 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 AME Study

NCT01910506
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170 10 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

NCT01232413
View directory record Official record
Conditions
Healthy Subjects, Cardiac Repolarization
Interventions
Placebo, ASP1941, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

NCT06275841
View directory record Official record
Conditions
Healthy
Interventions
vepdegestrant, esomeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Two Different Lion's Mane Extracts (Lions Mane Fruiting Body & Lions Mane Fruiting Body With Mycellium) on Cognitive Performance, Subjective Affect, Serum Biomarkers, and Gut Microbiota in Healthy Adults

NCT07405957
View directory record Official record
Conditions
Healthy Adult Females, Healthy Adult Male
Interventions
Lion Mane (Hericium erinaceus) fruiting body extract - Nordic Origin, Lions Mane (Hericium erinaceus) Fruiting body and mycelium, Maltodextrin (Placebo)
Dietary Supplement · Other
Lead sponsor
Applied Food Sciences Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Adults With or Without Kidney Problems

NCT05992155
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

NCT01380561
View directory record Official record
Conditions
Healthy
Interventions
asimadoline
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 56 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Bioavailability Study

NCT02336594
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 10 mg, RDEA3170 2.5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803

NCT05286281
View directory record Official record
Conditions
Healthy
Interventions
PF-07265803
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 15, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

NCT05816356
View directory record Official record
Conditions
Healthy
Interventions
Decitabine, Tetrahydrouridine
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 15, 2026, 7:20 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

NCT07549919
View directory record Official record
Conditions
Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions
AJ201
Drug
Lead sponsor
AnnJi Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 15, 2026, 7:20 PM EDT